Vicenza, Italy, February 17, 2018 --(PR.com
)-- Asalaser’s 2017, whose therapeutic solutions centred on Laser Therapy in the Human and Veterinary sectors are present in over 80 countries in the world throughout all 5 continents, surpasses the already significant 2016 result by recording a +13%. A success which has been achieved thanks to a development plan based on 3 key pillars: research, internationalisation and training. “The 2017 result is certainly important," explains Roberto Marchesini, CEO of ASAlaser. "As it confirms that the path we have embarked on and the investments we have made during these years have been the right ones for our growth. Continuing in this manner is the guideline for 2018 as well, a year during which we will work towards achieving a further increase in turnover, forecast at 7%.”
+20%: human resources, the most important company asset
In order to achieve this objective, in 2017 ASAlaser increased the number of its direct staff by 20% and further staff entries are forecast for the current year, when the company will number over 50 people. “These people represent a primary asset for us: in fact, their professional growth goes hand in hand with that of the company. Investing in staff training is a must which is part of the company’s DNA.” This is also confirmed by the figures: more than 2000 hours of training were provided last year, structured in group and one to one courses on topics such as project management, leadership, in-depth analysis of a regulatory, technical and administrative nature.
Research: 14% of the turnover and more than 150 scientific studies
Finally, the funds for Research, which represents a constant commitment for ASAlaser, ensure continuity – in 2016 the Company allocated approximately 13.5% of the turnover, which was increased to 14% in 2017 – and a serious project: to study the biology of physical stress at a molecular and cellular level in order to achieve new therapeutic methods and technologies for sufferers of painful issues to the musculo-skeletal apparatus, but also in the field of tissue regeneration and bioengineering “To date, there are more than 150 scientific studies in the fields of research and clinical trials promoted by ASA. On average every year," explains Lucio Zaghetto, the Scientific & Educational Director. "There are 6/7 basic and clinical research programmes conducted directly by ASAcampus staff (the ASAlaser research division, ed.) and the same commitment is also scheduled for 2018.”
Turnover growth, increase in staff, continuing investments in scientific research, R&D and training: these are ASAlaser’s projects for 2018, the year the innovative TT therapeutic strategy and the HIRO TT device are established after their successful presentation at “MEDICA 2017 - World Forum for medicine.” Continuing its mission of development in the fields of pain management and tissue repair, the company is also working on further solutions for the current year, leading to laying the foundations of the new production site, suitable for ensuring the best quality of work.